Omnicell appoints Baird Radford as new CFO effective August 26

FORT WORTH, Texas - Omnicell, Inc. (NASDAQ:OMCL), a healthcare technology company currently trading below its InvestingPro Fair Value with a "GOOD" financial health score, announced Monday the appointment of Baird Radford as Executive Vice President and Chief Financial Officer, effective August 26, 2025.

Radford, who brings more than 30 years of experience in healthcare and technology finance, will succeed Nchacha Etta. The outgoing CFO will remain with the company in an advisory capacity through November 2025 to facilitate the transition.

Prior to joining Omnicell, Radford served as Chief Financial Officer at Allakos Inc., a biotechnology company focused on therapeutic antibodies. His previous roles include Senior Vice President of Finance at Aimmune Therapeutics and CFO at HeartFlow, an AI health-tech company. Radford has also held leadership positions at Intuitive Surgical, eBay, and PricewaterhouseCoopers.

"I deeply believe in Omnicell’s mission to be a trusted healthcare partner," Radford said in the press release.

Randall Lipps, Omnicell’s chairman, president, CEO, and founder, stated that Radford’s expertise would help align the company’s financial strategy with its innovation roadmap as it continues its transformation into a digitally-enabled medication management technology company.

Omnicell, founded in 1992, provides pharmacy and nursing care solutions through robotics, smart devices, and intelligent software workflows. The company aims to help healthcare facilities improve efficiency, reduce costs, and enhance supply chain control.

The announcement comes as part of Omnicell’s ongoing strategic initiatives to advance what it calls the "Autonomous Pharmacy" vision within the healthcare industry.

In other recent news, Omnicell reported impressive financial results for the second quarter of 2025, surpassing market expectations. The company achieved a non-GAAP earnings per share of $0.45, significantly higher than the anticipated $0.27, resulting in a 66.67% surprise. Omnicell’s revenue also exceeded forecasts, totaling $290.56 million compared to the expected $275.28 million, marking a 5.55% surprise. Despite these strong earnings, Piper Sandler adjusted its price target for Omnicell to $55, down from $57, citing ongoing tariff challenges related to China while maintaining an Overweight rating. Meanwhile, KeyBanc Capital Markets reiterated its Sector Weight rating on Omnicell after a series of meetings with company executives. These developments highlight the company’s robust performance and the challenges it faces in the current economic environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.